

Pediatric Clinical Trials Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas), By Region and Competition, 2020-2030F

<https://marketpublishers.com/r/P75369E7CE27EN.html>

Date: May 2025

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: P75369E7CE27EN

Abstracts

Market Overview

The Global Pediatric Clinical Trials Market was valued at USD 15.29 billion in 2024 and is projected to reach USD 23.67 billion by 2030, growing at a CAGR of 7.56% during the forecast period. Pediatric clinical trials focus on assessing the safety, efficacy, and appropriate dosing of drugs, medical devices, and therapies for infants, children, and adolescents. These trials are vital for addressing medical conditions unique to the pediatric population and ensuring age-appropriate treatments. Ethical considerations are paramount, with protocols involving informed consent from parents or guardians. Trials are structured to measure outcomes such as symptom improvement, disease progression, and safety. Rising pediatric disease incidence, such as pneumonia, which affects over 1,400 children per 100,000 globally each year, underscores the urgent need for targeted therapies. Pharmaceutical companies are responding by prioritizing pediatric studies to close treatment gaps, especially in high-burden regions like South Asia and Sub-Saharan Africa. Growing demand for specialized pediatric care and regulatory support further propels the market forward.

Key Market Drivers

Growing Focus on Rare Diseases

The increasing emphasis on rare or orphan diseases—many of which primarily affect children—is a major driver of pediatric clinical trials. With limited treatment options available, pediatric trials play a crucial role in drug development for these underserved conditions. Regulatory bodies such as the FDA and EMA incentivize this research through extended exclusivity periods, tax credits, and application fee waivers. Orphan drug designations can also expedite development timelines and enhance funding opportunities. In addition, patient advocacy groups actively collaborate with stakeholders to promote awareness and facilitate research efforts, thus boosting clinical trial activity in pediatric rare disease populations.

Key Market Challenges

Diversity and Representation

A major challenge in pediatric clinical trials is ensuring demographic diversity and inclusive representation. Without adequate participation from diverse racial, ethnic, and socioeconomic groups, trial results risk being non-generalizable and potentially biased. This underrepresentation can exacerbate healthcare disparities, particularly in conditions that disproportionately impact specific populations. Factors such as cultural differences, language barriers, and socioeconomic status can hinder participation, while the need for parental consent introduces additional complexity. Regulatory authorities increasingly emphasize inclusivity in trial design, and engagement with local communities is essential for building trust and overcoming recruitment challenges. Culturally competent communication strategies are critical for improving representation across pediatric studies.

Key Market Trends

Increasing Emphasis on Pediatric Drug Development

There is a growing focus on developing pediatric-specific medications, driven by both commercial potential and public health need. Advances in genomics, targeted therapies, and precision medicine are creating new pathways for pediatric drug development. Collaborative networks like the Pediatric Trials Network and the International Neonatal Consortium are supporting these efforts by pooling resources and patient data. Patient

advocacy groups and global health initiatives are further amplifying awareness and support for pediatric research. These developments are accelerating clinical trial activity and fostering innovation in pediatric therapeutics, especially in areas with historically limited treatment options.

Key Market Players

Bristol-Myers Squibb Company

Charles River Laboratories International Inc.

Covance Inc.

GlaxoSmithKline plc

ICON plc

IQVIA Inc.

Novartis AG

Pfizer, Inc.

Pharmaceutical Product Development, LLC

Syneos Health Inc.

Paidion Research, Inc.

The Emmes Company, LLC

Report Scope:

In this report, the Global Pediatric Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Clinical Trials Market, By Phase:

Phase I

Phase II

Phase III

Phase IV

Pediatric Clinical Trials Market, By Study Design:

Treatment Studies

Observational Studies

Pediatric Clinical Trials Market, By Therapeutic Area:

Respiratory Disease

Infectious Diseases

Oncology

Diabetes

Other Therapeutic Areas

Pediatric Clinical Trials Market, By Region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Clinical Trials Market.

Available Customizations:

Global Pediatric Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV)
 - 5.2.2. By Study Design (Treatment Studies and Observational Studies)
 - 5.2.3. By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas)

- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map

6. ASIA PACIFIC PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Phase
 - 6.2.2. By Study Design
 - 6.2.3. By Therapeutic Design
 - 6.2.4. By Country
- 6.3. Asia Pacific: Country Analysis
 - 6.3.1. China Pediatric Clinical Trials Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Phase
 - 6.3.1.2.2. By Study Design
 - 6.3.1.2.3. By Therapeutic Design
 - 6.3.2. India Pediatric Clinical Trials Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Phase
 - 6.3.2.2.2. By Study Design
 - 6.3.2.2.3. By Therapeutic Design
 - 6.3.3. Australia Pediatric Clinical Trials Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Phase
 - 6.3.3.2.2. By Study Design
 - 6.3.3.2.3. By Therapeutic Design
 - 6.3.4. Japan Pediatric Clinical Trials Market Outlook
 - 6.3.4.1. Market Size & Forecast
 - 6.3.4.1.1. By Value
 - 6.3.4.2. Market Share & Forecast

- 6.3.4.2.1. By Phase
- 6.3.4.2.2. By Study Design
- 6.3.4.2.3. By Therapeutic Design
- 6.3.5. South Korea Pediatric Clinical Trials Market Outlook
 - 6.3.5.1. Market Size & Forecast
 - 6.3.5.1.1. By Value
 - 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Phase
 - 6.3.5.2.2. By Study Design
 - 6.3.5.2.3. By Therapeutic Design

7. EUROPE PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Phase
 - 7.2.2. By Study Design
 - 7.2.3. By Therapeutic Design
 - 7.2.4. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. France Pediatric Clinical Trials Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Phase
 - 7.3.1.2.2. By Study Design
 - 7.3.1.2.3. By Therapeutic Design
 - 7.3.2. Germany Pediatric Clinical Trials Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Phase
 - 7.3.2.2.2. By Study Design
 - 7.3.2.2.3. By Therapeutic Design
 - 7.3.3. Spain Pediatric Clinical Trials Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast

- 7.3.3.2.1. By Phase
- 7.3.3.2.2. By Study Design
- 7.3.3.2.3. By Therapeutic Design
- 7.3.4. Italy Pediatric Clinical Trials Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Phase
 - 7.3.4.2.2. By Study Design
 - 7.3.4.2.3. By Therapeutic Design
- 7.3.5. United Kingdom Pediatric Clinical Trials Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Phase
 - 7.3.5.2.2. By Study Design
 - 7.3.5.2.3. By Therapeutic Design

8. NORTH AMERICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Phase
 - 8.2.2. By Study Design
 - 8.2.3. By Therapeutic Design
 - 8.2.4. By Country
- 8.3. North America: Country Analysis
 - 8.3.1. United States Pediatric Clinical Trials Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Phase
 - 8.3.1.2.2. By Study Design
 - 8.3.1.2.3. By Therapeutic Design
 - 8.3.2. Mexico Pediatric Clinical Trials Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast

- 8.3.2.2.1. By Phase
- 8.3.2.2.2. By Study Design
- 8.3.2.2.3. By Therapeutic Design
- 8.3.3. Canada Pediatric Clinical Trials Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Phase
 - 8.3.3.2.2. By Study Design
 - 8.3.3.2.3. By Therapeutic Design

9. SOUTH AMERICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Phase
 - 9.2.2. By Study Design
 - 9.2.3. By Therapeutic Design
 - 9.2.4. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Pediatric Clinical Trials Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Phase
 - 9.3.1.2.2. By Study Design
 - 9.3.1.2.3. By Therapeutic Design
 - 9.3.2. Argentina Pediatric Clinical Trials Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Phase
 - 9.3.2.2.2. By Study Design
 - 9.3.2.2.3. By Therapeutic Design
 - 9.3.3. Colombia Pediatric Clinical Trials Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast

- 9.3.3.2.1. By Phase
- 9.3.3.2.2. By Study Design
- 9.3.3.2.3. By Therapeutic Design

10. MIDDLE EAST AND AFRICA PEDIATRIC CLINICAL TRIALS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Phase
 - 10.2.2. By Study Design
 - 10.2.3. By Therapeutic Design
 - 10.2.4. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Pediatric Clinical Trials Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Phase
 - 10.3.1.2.2. By Study Design
 - 10.3.1.2.3. By Therapeutic Design
 - 10.3.2. Saudi Arabia Pediatric Clinical Trials Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Phase
 - 10.3.2.2.2. By Study Design
 - 10.3.2.2.3. By Therapeutic Design
 - 10.3.3. UAE Pediatric Clinical Trials Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Phase
 - 10.3.3.2.2. By Study Design
 - 10.3.3.2.3. By Therapeutic Design

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. GLOBAL PEDIATRIC CLINICAL TRIALS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product

15. PESTLE ANALYSIS

16. COMPETITIVE LANDSCAPE

- 16.1. Bristol-Myers Squibb Company
 - 16.1.1. Business Overview
 - 16.1.2. Company Snapshot
 - 16.1.3. Products & Services
 - 16.1.4. Financials (In case of listed companies)
 - 16.1.5. Recent Developments
 - 16.1.6. Key Personnel Details
- 16.1.. SWOT Analysis
- 16.2. Charles River Laboratories International Inc.
- 16.3. Covance Inc.
- 16.4. GlaxoSmithKline plc
- 16.5. ICON plc
- 16.6. IQVIA Inc.
- 16.7. Novartis AG
- 16.8. Pfizer, Inc.
- 16.9. Pharmaceutical Product Development, LLC

16.10.Syneos Health Inc.

16.11.Paidion Research, Inc.

16.12.The Emmes Company, LLC

17. STRATEGIC RECOMMENDATIONS

18. ABOUT US & DISCLAIMER

I would like to order

Product name: Pediatric Clinical Trials Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas), By Region and Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/P75369E7CE27EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P75369E7CE27EN.html>